Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial.
Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, Marme F, Schröder C, Huober J, Duhoux F, Vuylsteke P, Jager A, Brain E, Kümmel S, Pápai Z, Menke-van der Houven van Oordt C, Perjesi L, Mueller A, Brignone C, Triebel F. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial. Clin Cancer Res 2023
08.11.2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial.
08.11.2023
Clin Cancer Res 2023
Wildiers Hans, Armstrong Anne, Cuypere Eveline, Dalenc Florence, Dirix Luc, Chan Stephen, Marme Frederik, Schröder Carolina P, Huober Jens, Duhoux Francois P, Vuylsteke Peter, Jager Agnes, Brain Etienne, Kümmel Sherko, Pápai Zsuzsanna, Menke-van der Houven van Oordt Catharina Willemien, Perjesi Luca, Mueller Arndt-Christian, Brignone Chrystelle, Triebel Frederic
Weiter
